Medgenics, the developer of technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, reported that its wholly owned subsidiary Medgenics Medical Israel was awarded a government grant of up to NIS 8.1 million (approximately $2.2 million) from the Office of the Chief Scientist in Israel. The grant will be used to cover R&D expenses to support further clinical development of the company’s proprietary tissue-based Biopump platform technology. Medgenics holds offices in San Francisco, California and Misgav, Israel.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments